Table II.

Hardy-Weinberg equilibrium of LRP5 single-nucleotide polymorphisms between cases and controls.

SNPs	Controls	Male controls	Female controls	NSCLCs	Male NSCLCs	Female NSCLCs	ADCs	Male ADCs	Female ADCs	SCCs	Male SCCs	Female SCCs
Rs4930573	0.48	0.23	0.87	0.35	0.20	0.78	0.80	0.75	0.97	0.18	0.08	0.35
Rs312009	0.15	0.72	0.01	0.59	0.59	0.89	0.40	0.33	0.96	0.69	0.63	0.85
Rs312014	0.41	0.61	0.48	0.73	0.31	0.35	0.80	0.32	0.44	0.85	0.72	0.45
Rs3781590	0.30	0.17	0.66	0.04	0.14	0.16	0.20	0.59	0.19	0.10	0.12	0.51
Rs312015	0.94	0.88	0.75	0.60	0.23	0.37	0.98	0.29	0.23	0.41	0.58	0.19
Rs491347	0.17	0.28	0.29	0.76	0.20	0.12	0.48	0.06	0.20	0.64	0.83	0.35
Rs1784235	0.19	0.28	0.33	0.84	0.27	0.16	0.56	0.08	0.20	0.64	0.75	0.72
Rs648438	0.47	0.64	0.59	0.15	0.14	0.74	0.63	0.94	0.59	0.04	0.02	0.51
Rs3736228	0.10	0.19	0.24	0.97	0.23	0.06	0.79	0.08	0.08	0.79	0.91	0.72
Rs624947	0.73	0.81	0.44	0.04	0.03	0.70	0.16	0.10	0.83	0.13	0.16	0.51
Rs607887	0.25	0.32	0.47	0.65	0.19	0.24	0.53	0.08	0.27	0.92	0.98	0.72

LRP5, low-density lipoprotein receptor-related protein 5; SNP, single-nucleotide polymorphism; NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma.